These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 32941713)

  • 1. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
    Logan IT; Zaman S; Hussein L; Perrett CM
    J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
    Lee O; Masood M; Nutan F
    J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.
    Zhou J; Wang CP; Li J; Zhang HL; He CX
    Front Immunol; 2024; 15():1414136. PubMed ID: 39072330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
    Satoh TK; Neulinger MM; Stadler PC; Aoki R; French LE
    J Dermatol; 2024 Jan; 51(1):3-11. PubMed ID: 38031902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study.
    He CX; Guo L; Qu T; Jin HZ
    Front Immunol; 2024; 15():1421684. PubMed ID: 39170619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
    Mitropoulou G; Daccord C; Sauty A; Pasche A; Egger B; Aedo Lopez V; Letovanec I; Beigelman-Aubry C; Nicod LP; Lazor R
    Respiration; 2020; 99(2):181-186. PubMed ID: 31914436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
    Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
    Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
    Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
    Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
    Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
    J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.
    Bafaloukos D; Gazouli I; Bousmpoukea A; Molfeta A; Chatzichristou E; Samonis G; Vathiotis I
    Immunotherapy; 2024; 16(14-15):937-942. PubMed ID: 39258778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
    Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
    J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
    [No Abstract]   [Full Text] [Related]  

  • 14. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

  • 15. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
    Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
    J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
    Hung W; Cusnir I; Habib S; Smylie M; Solez K; Yacyshyn E
    Rheumatology (Oxford); 2021 Jun; 60(6):e190-e191. PubMed ID: 33367837
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.